When a drug called acipimox lowers free fatty acids in the blood, it does not change how the liver reduces its own glucose production after a meal in healthy people, even though blood sugar and insulin levels drop. This suggests that the liver’s glucose output is not the main reason for improved blood sugar control in this scenario.

We analyzed one assertion on whether acipimox affects how the liver stops making glucose after a meal in healthy adults. What we’ve found so far is that when acipimox lowers free fatty acids in the blood, it does not change the liver’s natural reduction of glucose production after eating — even though blood sugar and insulin levels go down [1]. This suggests that the liver’s own glucose output may not be the main factor behind the improved blood sugar levels seen with acipimox. Acipimox is a drug that reduces free fatty acids, which are fats circulating in the blood. After a meal, the liver normally slows down its glucose production to help keep blood sugar stable. In this case, even though acipimox helped lower blood sugar and raised insulin, the liver still reduced its glucose output the same way it normally would. That means something else — perhaps muscle uptake of glucose or other metabolic changes — might be responsible for the better blood sugar control, not the liver’s behavior. We only reviewed one assertion, and no studies contradicted it. But because the total number of studies analyzed is very small, we can’t say this applies broadly or that the mechanism is fully understood. The evidence we’ve reviewed so far leans toward acipimox not altering the liver’s post-meal glucose suppression, but more research would be needed to confirm this pattern across different groups or conditions. In everyday terms: taking acipimox helps lower blood sugar after meals, but it doesn’t seem to do so by telling the liver to make less glucose. Something else is likely going on.